

North America Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity

<https://marketpublishers.com/r/N6B151BB3315EN.html>

Date: November 2021

Pages: 116

Price: US\$ 2,295.00 (Single User License)

ID: N6B151BB3315EN

Abstracts

North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach \$27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 29 tables and 54 figures, this 116-page report “North America Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue (\$ mn) for 2019-2030 included in each section.

Recombinant Non-glycosylated Biosimilars

Insulin

Recombinant Human Growth Hormone (rHGH)

Granulocyte Colony Stimulating Factor

Interferon

Recombinant Glycosylated Biosimilars

Monoclonal Antibodies (mAb)

Erythropoietin (EPO)

Follicle Stimulating Hormone

Recombinant Peptides and Others

Tumor Necrosis Factor (TNF)-Inhibitor

Parathyroid Hormone

Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the North America market is segmented into the following sub-markets with annual revenue (\$ mn) for 2019-2030 included in each section.

Cancer

Autoimmune Disease

Blood Disorder

Diabetes

Growth Hormone Deficiency

Infectious Diseases

Other Indications

Based on Manufacturing, the North America market is segmented into the following sub-markets with annual revenue (\$ mn) for 2019-2030 included in each section.

Contract Manufacturing

Inhouse Manufacturing

Based on End User, the North America market is segmented into the following sub-markets with annual revenue (\$ mn) for 2019-2030 included in each section.

Hospitals and Clinics

Research Institutes

Other End Users

Geographically, the following national/local markets are fully investigated:

U.S.

Canada

Mexico

For each key country, detailed analysis and data for annual revenue (\$ mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

- 1.1 Industry Definition and Research Scope
 - 1.1.1 Industry Definition
 - 1.1.2 Research Scope
- 1.2 Research Methodology
 - 1.2.1 Overview of Market Research Methodology
 - 1.2.2 Market Assumption
 - 1.2.3 Secondary Data
 - 1.2.4 Primary Data
 - 1.2.5 Data Filtration and Model Design
 - 1.2.6 Market Size/Share Estimation
 - 1.2.7 Research Limitations
- 1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

- 2.1 Market Size and Forecast
 - 2.1.1 Impact of COVID-19 on World Economy
 - 2.1.2 Impact of COVID-19 on the Market
- 2.2 Major Growth Drivers
- 2.3 Market Restraints and Challenges
- 2.4 Emerging Opportunities and Market Trends
- 2.5 Porter's Fiver Forces Analysis

3 SEGMENTATION OF NORTH AMERICA MARKET BY PRODUCT TYPE

- 3.1 Market Overview by Product Type
- 3.2 Recombinant Non-glycosylated Biosimilars
 - 3.2.1 Insulin
 - 3.2.2 Recombinant Human Growth Hormone (rHGH)
 - 3.2.3 Granulocyte Colony Stimulating Factor
 - 3.2.4 Interferon
- 3.3 Recombinant Glycosylated Biosimilars
 - 3.3.1 Monoclonal Antibodies (mAb)
 - 3.3.2 Erythropoietin (EPO)
 - 3.3.3 Follicle Stimulating Hormone

3.4 Recombinant Peptides and Others

3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor

3.4.2 Parathyroid Hormone

3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others

4 SEGMENTATION OF NORTH AMERICA MARKET BY INDICATION

4.1 Market Overview by Indication

4.2 Cancer

4.3 Autoimmune Disease

4.4 Blood Disorder

4.5 Diabetes

4.6 Growth Hormone Deficiency

4.7 Infectious Diseases

4.8 Other Indications

5 SEGMENTATION OF NORTH AMERICA MARKET BY MANUFACTURING

5.1 Market Overview by Manufacturing

5.2 Contract Manufacturing

5.3 Inhouse Manufacturing

6 SEGMENTATION OF NORTH AMERICA MARKET BY END USER

6.1 Market Overview by End User

6.2 Hospitals and Clinics

6.3 Research Institutes

6.4 Other End Users

7 NORTH AMERICA MARKET 2019-2030 BY COUNTRY

7.1 Overview of North America Market

7.2 U.S.

7.3 Canada

7.4 Mexico

8 COMPETITIVE LANDSCAPE

8.1 Overview of Key Vendors

8.2 New Product Launch, Partnership, Investment, and M&A

8.3 Company Profiles

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

RELATED REPORTS

List Of Tables

LIST OF TABLES:

- Table 1. Snapshot of North America Biosimilars Market in Balanced Perspective, 2019-2030
- Table 2. Growth Rate of World GDP, 2020-2022
- Table 3. World Health Spending by Region, \$ bn, 2013-2020
- Table 4. Main Product Trends and Market Opportunities in North America Biosimilars Market
- Table 5. North America Biosimilars Market by Product Type, 2019-2030, \$ mn
- Table 6. North America Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, \$ mn
- Table 7. North America Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, \$ mn
- Table 8. North America Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, \$ mn
- Table 9. North America Biosimilars Market by Indication, 2019-2030, \$ mn
- Table 10. North America Biosimilars Market by Manufacturing, 2019-2030, \$ mn
- Table 11. North America Biosimilars Market by End User, 2019-2030, \$ mn
- Table 12. North America Biosimilars Market by Country, 2019-2030, \$ mn
- Table 13. U.S. Biosimilars Market by Product Type, 2019-2030, \$ mn
- Table 14. U.S. Biosimilars Market by Indication, 2019-2030, \$ mn
- Table 15. U.S. Biosimilars Market by End User, 2019-2030, \$ mn
- Table 16. FDA Approved Biosimilars in U.S., 2015-2020
- Table 17. U.S. Select Pending Biosimilar BLAs as of December 2020
- Table 18. U.S. Biosimilar Market Share (market share data through July 2020)
- Table 19. Canada Biosimilars Market by Product Type, 2019-2030, \$ mn
- Table 20. Canada Biosimilars Market by Indication, 2019-2030, \$ mn
- Table 21. Canada Biosimilars Market by End User, 2019-2030, \$ mn
- Table 22. Mexico Biosimilars Market by Product Type, 2019-2030, \$ mn
- Table 23. Mexico Biosimilars Market by Indication, 2019-2030, \$ mn
- Table 24. Mexico Biosimilars Market by End User, 2019-2030, \$ mn
- Table 25. Breakdown of World Market by Key Vendor, 2020, %
- Table 26. AMEGA Biotech S.A.: Company Snapshot
- Table 27. AMEGA Biotech S.A.: Business Segmentation
- Table 28. AMEGA Biotech S.A.: Product Portfolio
- Table 29. AMEGA Biotech S.A.: Revenue, 2018-2020, \$ mn

List Of Figures

LIST OF FIGURES:

Figure 1. Research Method Flow Chart

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation

Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030

Figure 4. North America Biosimilars Market, 2019-2030, \$ mn

Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019

Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area

Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area

Figure 8. Impact of COVID-19 on Business

Figure 9. Primary Drivers and Impact Factors of North America Biosimilars Market

Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million

Figure 11. World Population 65 and Over, % of Total Population, 1950-2060

Figure 12. Primary Restraints and Impact Factors of North America Biosimilars Market

Figure 13. Investment Opportunity Analysis

Figure 14. Porter's Five Forces Analysis of North America Biosimilars Market

Figure 15. Breakdown of North America Biosimilars Market by Product Type, 2019-2030, % of Revenue

Figure 16. North America Addressable Market Cap in 2021-2030 by Product Type, Value (\$ mn) and Share (%)

Figure 17. North America Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, \$ mn

Figure 18. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, \$ mn

Figure 19. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, \$ mn

Figure 20. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, \$ mn

Figure 21. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, \$ mn

Figure 22. North America Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, \$ mn

Figure 23. North America Biosimilars Market by Recombinant Glycosylated Biosimilars:

Monoclonal Antibodies (mAb), 2019-2030, \$ mn

Figure 24. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, \$ mn

Figure 25. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, \$ mn

Figure 26. North America Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, \$ mn

Figure 27. North America Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, \$ mn

Figure 28. North America Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, \$ mn

Figure 29. North America Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, \$ mn

Figure 30. Breakdown of North America Biosimilars Market by Indication, 2019-2030, % of Sales Revenue

Figure 31. North America Addressable Market Cap in 2021-2030 by Indication, Value (\$ mn) and Share (%)

Figure 32. North America Biosimilars Market by Indication: Cancer, 2019-2030, \$ mn

Figure 33. North America Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, \$ mn

Figure 34. North America Biosimilars Market by Indication: Blood Disorder, 2019-2030, \$ mn

Figure 35. North America Biosimilars Market by Indication: Diabetes, 2019-2030, \$ mn

Figure 36. North America Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, \$ mn

Figure 37. North America Biosimilars Market by Indication: Infectious Diseases, 2019-2030, \$ mn

Figure 38. North America Biosimilars Market by Indication: Other Indications, 2019-2030, \$ mn

Figure 39. Breakdown of North America Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue

Figure 40. North America Addressable Market Cap in 2021-2030 by Manufacturing, Value (\$ mn) and Share (%)

Figure 41. North America Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, \$ mn

Figure 42. North America Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, \$ mn

Figure 43. Breakdown of North America Biosimilars Market by End User, 2019-2030, % of Revenue

Figure 44. North America Addressable Market Cap in 2021-2030 by End User, Value (\$ mn) and Share (%)

Figure 45. North America Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, \$ mn

Figure 46. North America Biosimilars Market by End User: Research Institutes, 2019-2030, \$ mn

Figure 47. North America Biosimilars Market by End User: Other End Users, 2019-2030, \$ mn

Figure 48. Breakdown of North America Biosimilars Market by Country, 2019 and 2030, % of Revenue

Figure 49. Contribution to North America 2021-2030 Cumulative Market by Country, Value (\$ mn) and Share (%)

Figure 50. U.S. Biosimilars Market, 2019-2030, \$ mn

Figure 51. Biosimilar Approvals and Launches in U.S., 2015-2020

Figure 52. Canada Biosimilars Market, 2019-2030, \$ mn

Figure 53. Biosimilars Market in Mexico, 2019-2030, \$ mn

Figure 54. Growth Stage of North America Biosimilars Industry over the Forecast Period

I would like to order

Product name: North America Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity

Product link: <https://marketpublishers.com/r/N6B151BB3315EN.html>

Price: US\$ 2,295.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N6B151BB3315EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970